Table 3.
Factors associated with the new onset of HCC after HBV NAs use in cirrhotic patients.
| With HCC (n = 62) | Without HCC (n = 330) | P value | Cox-regression analysis | |||
|---|---|---|---|---|---|---|
| HR | 95% C.I | P value | ||||
| Age > 50 years old, n (%) | 41 (66.1) | 192 (58.2) | 0.24 | |||
| Male, n (%) | 53 (85.5) | 242 (73.4) | 0.05 | 1.99 | 0.88–4.48 | 0.10 |
| Diabetes, n/N (%) | 12/54 (22.4) | 63/303 (20.8) | 0.86 | |||
| BMI (kg/m2, mean [SD])a | 26.1 (3.8) | 25.2 (4.1) | 0.13 | 1.11 | 1.03–1.19 | 0.01 |
| Platelet count (×103u/L, mean (SD)) | 111.0 (71.3) | 123.3 (58.1) | 0.15 | 1.00 | 0.99–1.00 | 0.09 |
| AST (IU/L, mean (SD)) | 154.9 (201.4) | 174.3 (308.8) | 0.64 | |||
| ALT (IU/L, mean (SD)) | 152.1 (201.5) | 182.5 (305.9) | 0.45 | |||
| Creatinine (mg/dL, mean (SD)) | 1.0 (0.9) | 1.1 (1.2) | 0.65 | |||
| HBV DNA (log10 IU/mL, mean (SD)) | 5.6 (1.7) | 5.4 (1.8) | 0.38 | |||
| HBV DNA > 2000 IU/mL, n/N (%) | 54 (87.1) | 28 (86.4) | 1.00 | |||
| HDV RNA positivity, n (%) | 2 (3.2) | 3 (0.9) | 0.18 | 4.45 | 1.04–19.09 | 0.04 |
| HBeAg positivity, n/N (%) | 17/61 (27.9) | 65/328 (19.8) | 0.17 | 0.97 | 0.47–2.01 | 0.94 |
SD: standard deviation; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HDV: hepatitis D virus; HBeAg: hepatitis B e-antigen; FIB-4: fibrosis-4 index; HCC: hepatocellular carcinoma; NAs: nucleotide analogues; HR: hazard ratio; CI: confidence interval.
an = 384.